Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1987 Nov;92(3):505–512. doi: 10.1111/j.1476-5381.1987.tb11350.x

Postsynaptic alpha-adrenoceptor reserve and the shift of the concentration-response curves to the right, as caused by the irreversible alpha-adrenoceptor antagonist phenoxybenzamine.

S Guimarães 1, M Q Paiva 1
PMCID: PMC1853684  PMID: 2892552

Abstract

1. The effect of different concentrations of phenoxybenzamine (0.1, 0.3, 1, 3, 10 and 30 nmoll -1) on the concentration-response curves to phenylephrine (a selective alpha 1-adrenoceptor agonist) and noradrenaline (a mixed alpha 1- and alpha 2-adrenoceptor agonist) was compared in two kinds of vascular tissue: dog saphenous vein (has both postsynaptic alpha 1- and alpha 2-adrenoceptors) and dog mesenteric and renal arteries--where only postsynaptic alpha 1-adrenoceptors have been shown to exist. 2. In the saphenous vein, where both alpha 1- and alpha 2-adrenoceptors coexist, at only one concentration of phenoxybenzamine, 3 nmoll -1, the concentration-response curve of noradrenaline was shifted to the right without a reduction of the maximum; and this shift was small (by 0.4 log units). 3. In tissues where only alpha 1-adrenoceptors exist postsynaptically (mesenteric and renal arteries) phenoxybenzamine never caused any shift of the noradrenaline concentration-response curves to the right without depressing the maximum effect. 4. In none of the tissues did phenoxybenzamine at any concentration shift the concentration-response curve of phenylephrine to the right without depressing its maximum. 5. All these results indicate that in the dog saphenous vein there is a 'false' alpha-adrenoceptor reserve for noradrenaline, since two kinds of receptors participate in the response to this amine. 6. The calculation of the occupancy-response relationship for the renal artery showed that 24% of the maximal response occurs when only 2% of alpha 1-adrenoceptors are activated and 50% of maximum at 9% occupation. However, for 95% of the maximal response an 83% occupancy is required.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
505

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Black J. W., Duncan W. A., Shanks R. G. Comparison of some properties of pronethalol and propranolol. Br J Pharmacol Chemother. 1965 Dec;25(3):577–591. doi: 10.1111/j.1476-5381.1965.tb01782.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. De Mey J. G., Vanhoutte P. M. Differences in pharmacological properties of postjunctional alpha-adrenergic receptors among arteries and veins. Arch Int Pharmacodyn Ther. 1980 Apr;244(2):328–329. [PubMed] [Google Scholar]
  3. Dubocovich M. L., Langer S. Z. Negative feed-back regulation of noradrenaline release by nerve stimulation in the perfused cat's spleen: differences in potency of phenoxybenzamine in blocking the pre- and post-synaptic adrenergic receptors. J Physiol. 1974 Mar;237(3):505–519. doi: 10.1113/jphysiol.1974.sp010495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Guimarães S., Brandão F., Paiva M. Q. A study of the adrenoceptor-mediated feedback mechanism by using adrenaline as a false transmitter. Naunyn Schmiedebergs Arch Pharmacol. 1978 Nov;305(2):185–188. doi: 10.1007/BF00508291. [DOI] [PubMed] [Google Scholar]
  5. Guimarães S. Further study of the adrenoceptors of the saphenous vein of the dog: influence of factors which interfere with the concentrations of agonists at the receptor level. Eur J Pharmacol. 1975 Nov;34(1):9–19. doi: 10.1016/0014-2999(75)90220-4. [DOI] [PubMed] [Google Scholar]
  6. Guimarães S., Osswald W. Adrenergic receptors in the veins of the dog. Eur J Pharmacol. 1969 Jan;5(2):133–140. doi: 10.1016/0014-2999(69)90021-1. [DOI] [PubMed] [Google Scholar]
  7. Guimarães S., Paiva M. Q., Moura D. Alpha 2-adrenoceptor-mediated responses to so-called selective alpha 1-adrenoceptor agonists after partial blockade of alpha 1-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 1987 Apr;335(4):397–402. doi: 10.1007/BF00165554. [DOI] [PubMed] [Google Scholar]
  8. Guimarães S., Paiva M. Q. The role played by the extraneuronal system in the disposition of noradrenaline and adrenaline in vessels. Naunyn Schmiedebergs Arch Pharmacol. 1977 Feb;296(3):279–287. doi: 10.1007/BF00498694. [DOI] [PubMed] [Google Scholar]
  9. Hamilton C. A., Reid J. L., Sumner D. J. Acute effects of phenoxybenzamine on alpha-adrenoceptor responses in vivo and in vitro: relation of in vivo pressor responses to the number of specific adrenoceptor binding sites. J Cardiovasc Pharmacol. 1983 Sep-Oct;5(5):868–873. doi: 10.1097/00005344-198309000-00025. [DOI] [PubMed] [Google Scholar]
  10. Iversen L. L., Salt P. J. Inhibition of catecholamine Uptake-2 by steroids in the isolated rat heart. Br J Pharmacol. 1970 Nov;40(3):528–530. doi: 10.1111/j.1476-5381.1970.tb10637.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Laher I., Nishimura S., Bevan J. A. Prazosin selectively antagonizes norepinephrine contractions at low-affinity, non-alpha adrenoceptor sites (extraceptors) in arterial muscle. J Pharmacol Exp Ther. 1986 Dec;239(3):846–852. [PubMed] [Google Scholar]
  12. Minneman K. P., Johnson R. D. Characterization of alpha-1 adrenergic receptors linked to [3H]inositol metabolism in rat cerebral cortex. J Pharmacol Exp Ther. 1984 Aug;230(2):317–323. [PubMed] [Google Scholar]
  13. Polónia J. J., Paiva M. Q., Guimarães S. Pharmacological characterization of postsynaptic alpha-adrenoceptor subtypes in five different dog arteries in-vitro. J Pharm Pharmacol. 1985 Mar;37(3):205–208. doi: 10.1111/j.2042-7158.1985.tb05043.x. [DOI] [PubMed] [Google Scholar]
  14. Ruffolo R. R., Jr, Morgan E. L., Messick K. Possible relationship between receptor reserve and the differential antagonism of alpha-1 and alpha-2 adrenoceptor-mediated pressor responses by calcium channel antagonists in the pithed rat. J Pharmacol Exp Ther. 1984 Sep;230(3):587–594. [PubMed] [Google Scholar]
  15. Ruffolo R. R., Jr, Yaden E. L. Existence of spare alpha 1-adrenoreceptors, but not alpha 2-adrenoreceptors, for respective vasopressor effects of cirazoline and B-HT 933 in the pithed rat. J Cardiovasc Pharmacol. 1984 Nov-Dec;6(6):1011–1019. [PubMed] [Google Scholar]
  16. Ruffolo R. R., Jr, Zeid R. L. Relationship between alpha adrenoceptor occupancy and response for the alpha-1 adrenoceptor agonist, cirazoline, and the alpha-2 adrenoceptor agonist, B-HT 933, in canine saphenous vein. J Pharmacol Exp Ther. 1985 Dec;235(3):636–643. [PubMed] [Google Scholar]
  17. STEPHENSON R. P. A modification of receptor theory. Br J Pharmacol Chemother. 1956 Dec;11(4):379–393. doi: 10.1111/j.1476-5381.1956.tb00006.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Shepperson N. B., Langer S. Z. The effects of the 2-amino-tetrahydronaphthalene derivative M7, a selective alpha 2-adrenoceptor agonist in vitro. Naunyn Schmiedebergs Arch Pharmacol. 1981 Dec;318(1):10–13. doi: 10.1007/BF00503305. [DOI] [PubMed] [Google Scholar]
  19. Starke K. Alpha-adrenoceptor subclassification. Rev Physiol Biochem Pharmacol. 1981;88:199–236. [PubMed] [Google Scholar]
  20. Starke K., Endo T., Taube H. D. Relative pre- and postsynaptic potencies of alpha-adrenoceptor agonists in the rabbit pulmonary artery. Naunyn Schmiedebergs Arch Pharmacol. 1975;291(1):55–78. doi: 10.1007/BF00510821. [DOI] [PubMed] [Google Scholar]
  21. Sullivan A. T., Drew G. M. Pharmacological characterisation of pre- and postsynaptic alpha-adrenoceptors in dog saphenous vein. Naunyn Schmiedebergs Arch Pharmacol. 1980 Nov;314(3):249–258. doi: 10.1007/BF00498546. [DOI] [PubMed] [Google Scholar]
  22. Trendelenburg U. Mechanisms of supersensitivity and subsensitivity to sympathomimetic amines. Pharmacol Rev. 1966 Mar;18(1):629–640. [PubMed] [Google Scholar]
  23. Vanhoutte P. M., Flavahan N. A. Effects of temperature on alpha adrenoceptors in limb veins: role of receptor reserve. Fed Proc. 1986 Aug;45(9):2347–2354. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES